Provectus Biopharmaceuticals (PVCT) Stock Chart & Stock Price History $0.12 -0.01 (-4.38%) (As of 11/29/2024 06:29 PM ET) Add Compare Share Share Chart Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Provectus Biopharmaceuticals Stock Price Performance 5 Day Performance+2.48%1 Month Performance+14.34%3 Month Performance+31.11%6 Month Performance-30.59%Year-To-Date Performance+22.92%1 Year Performance-24.31% Receive PVCT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Your bank is lying to you. (Ad)You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.View the best savings account rates here PVCT Stock Chart for Sunday, December, 1, 2024 PVCT Chart by TradingView Provectus Biopharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/29/2024$0.12$0.12-4.38%$0.12$0.1286,700 shs$49.59 million11/28/2024$0.12$0.12$0.12$0.12443,642 shs$51.86 million11/27/2024$0.12$0.12+7.16%$0.12$0.12443,642 shs$51.86 million11/26/2024$0.12$0.12-2.58%$0.12$0.11235,000 shs$48.40 million11/25/2024$0.12$0.12-1.42%$0.12$0.1265,130 shs$49.68 million11/22/2024$0.11$0.12+4.22%$0.12$0.11289,851 shs$49.80 million Get the Latest News and Ratings for PVCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/21/2024$0.11$0.11+3.27%$0.11$0.1172,285 shs$47.79 million11/20/2024$0.11$0.11+0.05%$0.11$0.11251,750 shs$46.27 million11/19/2024$0.11$0.11-1.74%$0.11$0.10205,979 shs$46.25 million11/18/2024$0.11$0.11+1.73%$0.11$0.10312,800 shs$47.07 million11/15/2024$0.11$0.11-0.81%$0.11$0.11837,440 shs$46.27 million11/14/2024$0.11$0.11-0.45%$0.11$0.11762,932 shs$46.65 million11/13/2024$0.11$0.11-1.68%$0.12$0.11452,914 shs$46.86 million11/12/2024$0.11$0.11+5.88%$0.11$0.11517,506 shs$47.66 million11/11/2024$0.11$0.11-0.83%$0.11$0.1030,841 shs$45.01 million11/08/2024$0.11$0.11-1.82%$0.11$0.10346,235 shs$45.39 million11/07/2024$0.11$0.11-3.34%$0.11$0.106,013 shs$46.23 million11/06/2024$0.11$0.11+4.12%$0.11$0.1059,139 shs$47.83 million11/05/2024$0.11$0.11+1.30%$0.11$0.1140,605 shs$45.94 million11/04/2024$0.10$0.11+4.55%$0.11$0.1054,600 shs$45.35 million11/01/2024$0.11$0.10-4.00%$0.11$0.10153,474 shs$43.37 million10/31/2024$0.11$0.11+0.47%$0.11$0.10127,951 shs$45.18 million10/30/2024$0.11$0.11+0.66%$0.11$0.10253,161 shs$44.97 million Related Companies ZURA Stock Price Chart DMAC Stock Price Chart CKPT Stock Price Chart EDIT Stock Price Chart ADCT Stock Price Chart TSVT Stock Price Chart ENTA Stock Price Chart NLTX Stock Price Chart MDWD Stock Price Chart FULC Stock Price Chart Receive PVCT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:PVCT) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored***TODAY ONLY*** Is this Trump’s Favorite Coin?Donald Trump just emphatically became America's first crypto president. Trump plans to make America, "the...Weiss Ratings | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | SponsoredBlack Friday: 59% dividend from Bitcoin (No Crypto Needed)Get a 59% Dividend from Bitcoin—No Crypto Required! Our Black Friday special reveals the "Bitcoin Income Va...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
